Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Low Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Large-scale testing (Phase 3)Active Not RecruitingNCT04494425
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
AstraZeneca 866
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Testing effectiveness (Phase 2)Study completedNCT03052634
What this trial is testing

RC48-ADC in Subjects With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
RemeGen Co., Ltd. 112
Testing effectiveness (Phase 2)Looking for participantsNCT06439771
What this trial is testing

Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 180
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07757230
What this trial is testing

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 87
Testing effectiveness (Phase 2)Active Not RecruitingNCT03917082
What this trial is testing

Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer

Who this might be right for
Breast Cancer FemaleHormone Receptor Positive Tumor
British Columbia Cancer Agency 290
Testing effectiveness (Phase 2)Looking for participantsNCT06263543
What this trial is testing

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Who this might be right for
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+2 more
Reshma L. Mahtani, D.O. 75
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07368543
What this trial is testing

Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Fudan University 216
Testing effectiveness (Phase 2)Looking for participantsNCT06330064
What this trial is testing

Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Who this might be right for
Recurrent or Metastatic Solid Tumors
Daiichi Sankyo 680
Testing effectiveness (Phase 2)Looking for participantsNCT07192432
What this trial is testing

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Who this might be right for
HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc. 27
Testing effectiveness (Phase 2)Looking for participantsNCT06227117
What this trial is testing

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 120
Testing effectiveness (Phase 2)Looking for participantsNCT06797635
What this trial is testing

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 372
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701941
What this trial is testing

Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor PositiveHER2-low or HER2-ultralowUnresectable or Metastatic Breast Cancer
Daiichi Sankyo 220
Large-scale testing (Phase 3)Looking for participantsNCT07762885
What this trial is testing

Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery

Who this might be right for
Ductal Carcinoma In Situ, DCIS
Fudan University 636
Not applicableStudy completedNCT05913440
What this trial is testing

HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

Who this might be right for
Breast Cancer
AstraZeneca 1,669
Not applicableStudy completedNCT07587983
What this trial is testing

Real-World Treatment of ADC-Resistant HER2-Low Advanced Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 220
Large-scale testing (Phase 3)Looking for participantsNCT05950945
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Daiichi Sankyo 250
Testing effectiveness (Phase 2)Study completedNCT02614794
What this trial is testing

Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen Inc. 612
Not applicableNot Yet RecruitingNCT06711094
What this trial is testing

Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

Who this might be right for
HR+/HER2- Advanced Breast Cancer
Fujian Medical University 52
Next Page